What is Zacks Research's Forecast for Surmodics Q3 Earnings?

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Research analysts at Zacks Research cut their Q3 2025 EPS estimates for Surmodics in a note issued to investors on Tuesday, April 29th. Zacks Research analyst D. Dey now forecasts that the company will post earnings of $0.00 per share for the quarter, down from their prior forecast of $0.02. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics' Q4 2025 earnings at $0.08 EPS, Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.04 EPS, Q1 2027 earnings at $0.10 EPS, Q2 2027 earnings at $0.11 EPS and FY2027 earnings at $0.38 EPS.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.07). The company had revenue of $28.09 million during the quarter, compared to analysts' expectations of $32.23 million. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%.

SRDX has been the subject of several other reports. Needham & Company LLC reiterated a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th. StockNews.com started coverage on shares of Surmodics in a report on Monday, February 3rd. They issued a "hold" rating on the stock. Finally, Lake Street Capital upgraded Surmodics from a "hold" rating to a "buy" rating and set a $43.00 target price for the company in a research note on Friday, March 7th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $43.00.

Surmodics Trading Down 2.4 %

NASDAQ SRDX traded down $0.67 during mid-day trading on Thursday, hitting $26.97. The company's stock had a trading volume of 83,317 shares, compared to its average volume of 277,437. The stock's fifty day simple moving average is $29.43 and its two-hundred day simple moving average is $34.86. Surmodics has a 52-week low of $26.00 and a 52-week high of $42.44. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29. The firm has a market capitalization of $385.64 million, a P/E ratio of -26.70 and a beta of 1.32.

Institutional Trading of Surmodics

Several institutional investors have recently added to or reduced their stakes in SRDX. Modus Advisors LLC acquired a new position in Surmodics during the 4th quarter valued at approximately $40,000. R Squared Ltd bought a new position in shares of Surmodics during the fourth quarter worth about $55,000. Legal & General Group Plc increased its holdings in shares of Surmodics by 34.2% in the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock worth $137,000 after acquiring an additional 880 shares during the period. Price T Rowe Associates Inc. MD bought a new stake in Surmodics in the 4th quarter valued at about $217,000. Finally, Polymer Capital Management US LLC acquired a new position in Surmodics during the 4th quarter valued at about $255,000. Institutional investors own 96.63% of the company's stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).